RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corporation is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, the Company's discovery and clinical development programs are based on its proprietary self-delivering RNAi (sd-rxRNA®) platform and Samcyprone™, a small molecule topical immunomodulator. Current clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.

Expert Comments:

Management Q&A: View From the Top
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
read more >
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts.
read more >
Marcel Wijma, Van Leeuwenhoeck Research (5/22/17)
"RXi Pharmaceuticals Corp. announced that it has extended its existing agreement with the Norwegian biotech company PCI Biotech. This extension is supported by a new preclinical research collaboration agreement that reflect RXi's recently completed acquisition of MirImmune and PCI Biotech's focus in oncology. . .both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be jointly owned by the companies. . .we have increased our valuation on RXi Pharmaceuticals to $4.50- 5.50 USD per share."

Marcel Wijma, Van Leeuwenhoeck Research (5/17/17)
"RXi Pharmaceuticals Corp. developed a robust RNAi therapeutic platform including self-delivering RNA (sd-rxRNA) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. . .we have increased our valuation on RXi Pharmaceuticals Corp. to USD 100-125 million or USD 4.50-5.50 per share. . .due to the fact that we have increased our likelihood of approval and market potential for RXi's lead product RXI-109. At this moment we do not address value to the preclinical programs in RXi's pipeline."

Keith Markey, Griffin Securities (5/4/17)
"RXi Pharmaceuticals Corp. added a multi-faceted oncology platform to its R&D pipeline with the January acquisition of MirImmune. Now the Company has five compounds targeting checkpoint inhibitors that should enjoy a significant cost advantage over today's antibodybased inhibitors and a sixth that is designed to prevent cytokine release syndrome. . .based on the new checkpoint inhibitors and the potential for multiple partnering deals, we believe a $6.50 price target is achievable and we are maintaining our BUY recommendation."

Marcel Wijma, Van Leeuwenhoeck Research (2/13/17)
"Based on our net present value valuation, we believe that RXi Pharmaceuticals Corp. is substantially undervalued at the current share price of $0.74. Using our valuation model and taking into account the further development of its pipeline including the acquisition of MirImmune, the company's current total value should be $75-100M, or $4.50-6/share; this represents a substantial upside from the current share price."

Donovan Jones, Seeking Alpha (12/15/16)
"RXi Pharmaceuticals Corp. secured an exclusive option to acquire MirImmune, a company developing cell-based immunotherapies for the treatment of cancers such as ovarian cancer and melanoma. . .for its lead candidate RXI-109 for the treatment of dermal scarring. . .the preliminary data showed positive differentiation between control and treated subjects after surgical incisions at all time points through nine months post-surgery. RXi expects a complete results announcement in mid-2017. . .RXII's offering is a Buy, based on a promising outlook for its leading scar treatment candidate."

More Expert Comments

Experts Following This Company

Alexey Eliseev, former Chief Business Officer at RXII – RXi Pharmaceuticals Corp.
Keith Markey, Scientific Director – Griffin Securities
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters, the company and other contributors.

RXi Pharmaceuticals Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
RXi has developed a robust, proprietary RNAi therapeutic platform
RNAi has the ability to “silence” a specific gene in a disease condition
Extensive patent estate provides for multiple development and commercialization of RNAi therapeutics